Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: Current status and future directions

Pediatric Nephrology

Volumn 20, Issue 10, 2005, Pages 1376-1381

  Moudgil, Asha ^a   Bagga, Arvind ^b   Jordan, Stanley C ^c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic renal failure; Focal segmental glomerulosclerosis; Mycophenolate mofetil; Nephrotic syndrome; Steroid dependence; Steroid resistance

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; GLUCURONOSYLTRANSFERASE; LEVAMISOLE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ACNE; ALOPECIA; AREA UNDER THE CURVE; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BONE MINERALIZATION; CANCER RISK; CATARACT; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CUSHINGOID SYNDROME; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DYSLIPIDEMIA; EDITORIAL; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; GONADAL DISEASE; GROWTH RETARDATION; HEMORRHAGIC CYSTITIS; HIRSUTISM; HISTOPATHOLOGY; HUMAN; HYPERKALEMIA; HYPERTENSION; INFECTION RISK; KIDNEY FUNCTION; LONG TERM CARE; MOOD DISORDER; NEPHROTIC SYNDROME; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; RACE DIFFERENCE; RELAPSE; REMISSION; SIDE EFFECT; TREATMENT WITHDRAWAL; TREMOR; WEIGHT GAIN;

DRUG RESISTANCE; HUMANS; IMP DEHYDROGENASE; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; RETREATMENT; STEROIDS;

EID: 26044470520     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-005-1964-z     Document Type: Editorial

References (58)

1. Churg J, Habib R, White RHR (1970) Pathology of nephrotic syndrome in children: A report for the International Study of Kidney Disease in Children. Lancet 760:1299-1302 10.1016/S0140-6736(70)91905-7
2. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P (1993) Cyclosporine versus cyclophosphamide for patients with steroid dependent and frequently relapsing idiopathic nephrotic syndrome: A multicenter randomized controlled trial. Nephrol Dial Transplant 8:1326-1332
3. Inoue Y, Iijima K, Nakamura H, Yoshikawa N (1999) Two-year cyclosporine treatment in children with steroid dependent nephrotic syndrome. Pediatr Nephrol 13:33-38 10.1007/s004670050558
4. Cattran DC. Appel GB. Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL for the North America Nephrotic Syndrome Study Group (1999) A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis Kidney Int 56:2220-2226
5. Habib R, Klein knechtle (1971) The primary nephrotic syndrome of childhood-classification and clinicopathologic study of 406 cases. Path Annu 6:417-474 1:STN:280:CSyD3M7ivFU%3D
6. Durkan AM, Hodson EM, Willis NS, Craig JC (2001) Immunosuppressive agents in childhood nephrotic syndrome: A meta-analysis of randomized controlled trials. Kidney Int 59:1919-1927 10.1046/ j.1523-1755.2001.0590051919.x
7. Filler G (2003) Treatment of nephrotic syndrome in children and controlled trials. Nephrol Dial Transplant [Suppl 6]:75-7810
8. Choi MJ, Eustacew JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA (2002). Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61:1098-1114 10.1046/j.1523-1755.2002.00214.x
9. Chandra M, Susin M, Abitbol C (2000) Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. Pediatr Nephrol 14:224-226 10.1007/s004670050047
10. Bagga A, Hari P, Moudgil A, Jordan SC (2003) Mycophenolate mofetil and prednisolone therapy in steroid dependent nephrotic syndrome. Am J Kidney Dis 42:1114-1120 10.1053/j.ajkd.2003.08.011
11. Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil (2004) Pediatr Nephrol 19:101-104 10.1007/s00467-003-1300-4
12. Ehrlich JH, Brodehl J (1993) Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Eur J pediatr 152:357-61 8482290
13. Hiraoka M, Tsukahara H, Matsubara K, Tsurusawa M, Takeda N, Haruki S, Hayashi S, Ohta K, Momoi T, Ohshima Y, Sugunuma N, Mayumi M, for the West Japan Cooperative Study of Kidney Disease in Children (2003) A randomized study of two long- course prednisolone regimens for nephrotic syndrome in children. Am J Kidney Dis 41:1155-1162 10.1016/ S0272-6386(03)00346-9
14. Vester U, kranz B, Zimmerman S, Hoyer PF (2003) Cyclophosphamide in steroid-sensitive nephrotic syndrome: Outcome and outlook. Pediatr Nephrol 7:661-664
15. Donia AF, Gazareen SH, Ahmed HA, Shoeib AA, Ismail AM, Khamis S, Sobh MA (2003) Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid dependent children. Nephrol Dial Transplant 10:2054-2058
16. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM (2002) Fertility after treatment for Hodgkin's disease. Ann Oncol 13 [Suppl 1]:138-147
17. Niaudet P (1992). Comparison of cyclosporine and chlorambucil in the treatment of steroid-dependent nephrotic syndrome: A multicentric randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 6:1-3 10.1007/BF00856817
18. Habashi D, Hodson E, Craig J (2004) Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane database system review 2: CD 003594
19. Iijima K, Hamashira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N (2002) Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 61:1801-1805 10.1046/j.1523-1755.2002.00303.x
20. McCauley J, Shapiro R, Ellis D, Igdal H, Tzakis A, Starzl TE (1993) Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 11:1286-1290
21. Schweda FLiebl R, Riegger GA, Kramer BK (1997) Tacrolimus treatment for steroid- and cyclosporine- resistant minimal change nephrotic syndrome. Nephrol Dial Transplant 12:2433-2443
22. Moxey-Mims MM, Kay C, Light JA, Kher KK (1998) Increased incidence of insulin dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK 506). Transplantation 65:617-619 10.1097/00007890-199803150-00003
23. Niaudet P, Drachman R, Gagnadoux MF, Broyer M (1984) Treatment of idiopathic nephrotic syndrome with levamisole. Acta Pediatr Scand 73:637-641
24. British Association for Paediatric Nephrology (1991) Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. Lancet 337:1555-1557 1675705
25. Bagga A, Sharma A, Srivastava RN (1997) Levamisole therapy in corticosteroid dependent nephrotic syndrome. Pediatr Nephrol 11:415-417 10.1007/s004670050307
26. Barbano G, Ginevri F, Ghiggeri GM, Gusmano R (1999) Disseminated autoimmune disease during levamisole treatment of nephrotic syndrome. Pediatr Nephrol 13:602-603 10.1007/s004670050753
27. Barratt TM, Cameron JS, Chantler C, Counahan R, Ogg CS, Soothill JF (1977) Controlled trial of azathioprine in treatment of steroid responsive nephrotic syndrome of childhood. Arch Dis Child 52:462-463 1:STN:280:CSiB38%2Flt1w%3D
28. Hiraoka M, Tsukahara H, Hori C, Oshima Y, Momoi T, Seo A, Mayumi M (2000) Efficacy of long-term azathioprine for relapsing nephrotic syndrome. Pediatr Nephrol 14:776-778 1:STN:280:DC%2BD3M%2FktlylsQ%3D%3D
29. Laurent AF, Dumont S, Poindron P, Muller CD (1996) Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and some substrates. Exp Hematol 24:59-67 1:CAS:528:DyaK28Xht1ajt7w%3D
30. Gummert JF, Barten MJ, Sherwood SW, Vangelder R, Billingham ME, Morris RE (1999) Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. Pharmacol Exp Ther 291:1100-1112
31. Remuzzi G, Zoja C, Gagliardini E, Coma D, Abbate M, Benigni A (1999) Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. JASN 10:1542-1549 1:CAS:528:DyaK1MXktlKhurc%3D
32. Day CJ, Cockwell P, Liokin GW, Savage CO, Howie AJ, Adu D (2002) Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 17:2011-2013 10.1093/ndt/17.11.2011
33. Mogyorosi A, Lippman HR, Feldman GM (2002) Successful treatment of steroid resistant minimal change disease with mycophenolate mofetil. Am J Nephrol 22:569-572 10.1159/000065276
34. Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB (2003) Use of mycophenolate mofetil in steroid-dependent and steroid-resistant nephrotic syndrome Pediatr Nephrol 18:833-837
35. Ulinski T, Duborg L, Said MH, Parchoux B, Ranchin B, Cochat P (2005) Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol 20:482-485 10.1007/s00467-004-1778-4
36. Montane B, Abitbol C, Chandar J, Strauss J, Jillerulo G (2003) Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 18:772-777 10.1007/s00467-003-1174-5
37. Zhao M, Chen X, Chen Y, Lieu Y, Lu F, Zhang Y, Wang H. Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome (2003) Nephrology (Carlton) 8:105-109
38. Neylan JF (1997). Immunosuppressive therapy in high-risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 64:1277-82. 10.1097/ 00007890-199711150-00008
39. Tejara N, Gomez-Garre D, Lazaro A, Gallego-Delgdo J, Alamo C, Blanco J, Oritz A Egido J (2004) Persistent proteinuria up-regulates angiotensin II type 2 receptor and induces apoptosis in proximal tubular cells. Am J Pathol 164:1817-1826 15111328
40. Contreras G, Parado V, Leclereg B, Lenz O, Tozman E, O'Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971-980 10.1056/NEJMoa031855
41. Ingulli E, Tejani A (1991) Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol 5:393-397 10.1007/BF01453661
42. Sorof J, Hawkins EP, Brewer ED, Boydstun II, Kale AS, Powell DR (1998) Age ethnicity affect the risk and outcome of focal segmental glomerulosclerosis. Pediatr Nephrol 12:764-768 10.1007/s004670050542
43. Grisweld WR, Tune BM, Reznik VM, Varquez M, Prime DJ, Brock P, Mendoza SA (1987) Treatment of childhood prednisone resistant nephrotic syndrome and focal segmental glomerulosclerosis with intravenous pulse methylprednisolone and oral alkylating agents. Nephron 46:73-77 3600915
44. Adhikari M, Bhimma R, Coovadia HM (1997) Intensive pulse therapies for focal glomerulosclerosis in South African children. Pediatr Nephrol 11:423-428 10.1007/s004670050309
45. Mendoza SA, Reznik VM, Grisweld WR, Krensky AM, Yorgin PD, Tune BM (1990) Treatment of steroid-resistant focal segmental glomerulosclerosis with intravenous pulse methylprednisolone and alkylating agents. Pediatr Nephrol 4:303-307 10.1007/BF00862503
46. Hari P, Bagga A, Jindal N, Srivastava RN (2001) Treatment of focal glomeulosclerosis with pulse steroids and cyclophosphamide. Pediatr Nephrol 16:901-905 10.1007/s004670100680
47. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Grisweld WR, Mendoza SA (1995) Intravenous pulse methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: A long-term follow-up. Clin Nephrol 43:84-88 1:STN:280:ByqB2Mvns1c%3D
48. Waldo FB, Benefield MR, Kohaut EC (1992) Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome. Pediatr Nephrol 6:503-505 10.1007/BF00866483
49. Elhence R, Gulati S, Kher V, Gupta A, Sharma RK (1994) Intravenous pulse cyclophosphamide - a new regime for steroid-resistant minimal change nephrotic syndrome. Pediatr Nephrol 8:1-3 10.1007/BF00868243
50. Rennert WP, Kala UK, Jacobs D, Goetsch S, Verhaart S (1999) Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis. Pediatr Nephrol 13:113-11651 10.1007/s004670050574
51. Bajpai A, Bagga A, Hari P, Dinda A, Srivastava RN (2003) Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome. Pediatr Nephrol 18:351-356 12700961
52. Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA (2000) Enalapril and prednisone in children with nephrotic-range proteinuria. Pediatr Nephrol 14:1088-1091 10.1007/s004679900244
53. Korbet SM (2003) Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 23:219-228 10.1053/ snep.2003.50020
54. Bullingham R, Monroe S, Nichols A. Hale M (1996) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single dose oral and intravenous administration. J Clin Pharmacol 36:315-324
55. Shaw LM, Korecka M, Venkatatamanan R, Goldberg L, Bloom R, Brayman KL (2003) Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 3:534-542
56. Weber LT, Shipakova M, Armstrong VW (2002) The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13:759-768 10.1097/01.ASN.0000027031.79843.6C
57. Nowak I, Shaw LM (1995) Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics. Clin Chem 41:1011-1017 1:CAS:528:DyaK2MXms1Gltbo%3D
58. Gataneo D, Perico N, Gaspari F, Gotti E, Remuzzi G (2002) Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 62:1060-1067 10.1046/ j.1523-1755.2002.00531.x